Automated isolation of primary antigen‐specific T cells from donor lymphocyte concentrates: results of a feasibility exercise. Issue 4 (7th May 2015)

• Record Type: Journal Article
• Authors: Bunos, M.; Hümmer, C.; Wingenfeld, E.; Sorg, N.; Pfirrmann, V.; Bader, P.; Seifried, E.; Bönig, H.
• Is Part Of: Vox sanguinis. Volume 109:Issue 4(2015)
• Page Start: 387
• Page End: 393
• Publication Date: 2015-05-07
• Subjects: Blood -- Periodicals; Blood -- Transfusion -- Periodicals; Immunohematology -- Periodicals; Immunopathology -- Periodicals; 615.39
• DOI: 10.1111/vox.12291
• Languages: English
• ISSNs: 0042-9007

Abstract

<abstract abstract-type="main" id="vox12291-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="vox12291-sec-0001" sec-type="section"> <title>Background</title> <p>The safety and clinical efficacy of adoptive transfer of prospectively isolated antigen‐specific T cells are well established. Several competing selection methods are available, one of which is based on immunomagnetic enrichment of T cells secreting IFNγ after incubation with the relevant antigen. The proprietary, GMP‐conforming selection technology, called 'cytokine capture system' (CCS) is established in many laboratories for the CliniMACS Plus system. It is robust and efficient, but labour‐intensive and incompatible with a single‐shift working schedule. An automatic immunomagnetic cell processing system, CliniMACS Prodigy ('Prodigy'), including a protocol for fully automatic CCS execution was recently released.</p> </sec> <sec id="vox12291-sec-0002" sec-type="section"> <title>Material and methods</title> <p>Feasibility of clinical‐scale CMV‐specific T‐cell selection using Prodigy was evaluated using leukoapheresis products from five healthy CMV sero‐positive volunteers. Clinical reagents and consumables were used throughout.</p> </sec> <sec id="vox12291-sec-0003" sec-type="section"> <title>Results</title> <p>The process required no operator input beyond set‐up and QC‐sample collection, that is, feasibility was given. An IFNγ‐secreting target T‐cell population was detectable after stimulation, and >2 log‐scale relative depletion of not CMV‐reactive T cells in the target population was achieved. Purity, that is the frequency of CMV‐reactive T cells among all CD3<sup>+</sup> cells ranged between 64 and 93%.</p> </sec> <sec id="vox12291-sec-0004" sec-type="section"> <title>Conclusion</title> <p>The CCS protocol on Prodigy is unrestrictedly functional. It runs fully automatically beyond set‐up and thus markedly reduces labour. The quality of the products generated is similar to products generated with CliniMACS Plus. The automatic system is thus suitable for routine clinical application.</p> </sec> </abstract>